EMJ Hematology 12 [Supplement 2] . 2024

In this issue

Don’t miss this interview with two co-authors of the ‘IMROZ’ study, the first global Phase III study of an anti-CD38 monoclonal antibody delivered in combination with the standard of care VRd (triplet combination of bortezomib, lenalidomide, dexamethasone) in patients with newly diagnosed multiple myeloma not intended for transplant. Results show an improvement in progression-free survival, with consistent responses, supporting the frontline use of Isa-VRd in patients not intended for transplant.